US FDA External Controls Guidance Does Little To Advance The Cause, Especially In Rare Diseases – Comments

 
• By Sue Sutter
Road obstruction
Stakeholders would like the FDA to take a less obstructionist approach to use of externally controlled trials. • Source: Shutterstock

More from Real-World Evidence

More from Clinical Trials